July 21 (Reuters) - Sarepta Therapeutics ( SRPT ) said

on Monday that it will pause all shipments of its Elevidys gene

therapy in the United States after a muscular dystrophy patient

who received a different, experimental treatment died.

U.S. regulators on Friday asked Sarepta Therapeutics ( SRPT ) to

voluntarily halt shipments of its gene therapy. However, the

company had first refused to do so.

All shipments of Elevidys for Duchenne muscular dystrophy

would be temporarily paused by close of business on Tuesday,

Sarepta said in a statement.